Vera Therapeutics, Inc. $VERA Shares Sold by GC Wealth Management RIA LLC

GC Wealth Management RIA LLC decreased its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 38.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,985 shares of the company’s stock after selling 14,900 shares during the quarter. GC Wealth Management RIA LLC’s holdings in Vera Therapeutics were worth $1,215,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Deerfield Management Company L.P. raised its position in shares of Vera Therapeutics by 8.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after acquiring an additional 293,040 shares in the last quarter. Vanguard Group Inc. increased its stake in Vera Therapeutics by 11.9% during the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after purchasing an additional 379,748 shares during the last quarter. Vestal Point Capital LP increased its stake in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the last quarter. Integral Health Asset Management LLC raised its holdings in shares of Vera Therapeutics by 47.8% during the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock worth $49,402,000 after purchasing an additional 550,000 shares during the period. Finally, Schroder Investment Management Group raised its holdings in shares of Vera Therapeutics by 82.4% during the third quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock worth $19,652,000 after purchasing an additional 307,243 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Insider Transactions at Vera Therapeutics

In related news, SVP Joseph R. Young sold 3,117 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $130,851.66. Following the completion of the transaction, the senior vice president owned 64,722 shares in the company, valued at $2,717,029.56. This represents a 4.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Sean Grant sold 4,949 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the transaction, the chief financial officer directly owned 114,181 shares in the company, valued at approximately $4,793,318.38. The trade was a 4.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 56,441 shares of company stock worth $2,416,902 over the last ninety days. Insiders own 15.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research note on Wednesday, March 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $81.45.

Vera Therapeutics Stock Down 3.4%

Shares of Vera Therapeutics stock opened at $35.84 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a 1-year low of $18.76 and a 1-year high of $56.05. The business’s fifty day moving average price is $40.48 and its two-hundred day moving average price is $40.15. The company has a market capitalization of $2.56 billion, a P/E ratio of -7.69 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period in the prior year, the company earned ($0.72) earnings per share. As a group, research analysts forecast that Vera Therapeutics, Inc. will post -5.33 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.